PT2970512T - Proteínas de fusão imunomoduladoras e métodos para produção das mesmas - Google Patents

Proteínas de fusão imunomoduladoras e métodos para produção das mesmas

Info

Publication number
PT2970512T
PT2970512T PT14779937T PT14779937T PT2970512T PT 2970512 T PT2970512 T PT 2970512T PT 14779937 T PT14779937 T PT 14779937T PT 14779937 T PT14779937 T PT 14779937T PT 2970512 T PT2970512 T PT 2970512T
Authority
PT
Portugal
Prior art keywords
methods
making same
immunomodulatory proteins
fusion
fusion immunomodulatory
Prior art date
Application number
PT14779937T
Other languages
English (en)
Inventor
Sastry Kedarnath
Melina Soares Maria
Govindappa Nagaraj
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of PT2970512T publication Critical patent/PT2970512T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PT14779937T 2013-03-12 2014-03-10 Proteínas de fusão imunomoduladoras e métodos para produção das mesmas PT2970512T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361777016P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
PT2970512T true PT2970512T (pt) 2019-01-17

Family

ID=51658871

Family Applications (1)

Application Number Title Priority Date Filing Date
PT14779937T PT2970512T (pt) 2013-03-12 2014-03-10 Proteínas de fusão imunomoduladoras e métodos para produção das mesmas

Country Status (16)

Country Link
US (3) US9988456B2 (pt)
EP (1) EP2970512B1 (pt)
JP (2) JP6605444B2 (pt)
CN (1) CN105121474B9 (pt)
AU (2) AU2014249405C1 (pt)
BR (1) BR112015022733B1 (pt)
CA (2) CA2902830C (pt)
DK (1) DK2970512T3 (pt)
ES (1) ES2704411T3 (pt)
HK (1) HK1217343A1 (pt)
MY (1) MY186864A (pt)
NZ (1) NZ711445A (pt)
PL (1) PL2970512T3 (pt)
PT (1) PT2970512T (pt)
RU (2) RU2662991C2 (pt)
WO (1) WO2014164427A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104334573A (zh) * 2012-04-30 2015-02-04 比奥孔有限公司 靶向/免疫调节性融合蛋白及其制造方法
PL2970512T3 (pl) * 2013-03-12 2019-03-29 Biocon Limited Immunomodulujące białka fuzyjne i sposoby ich otrzymywania
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
WO2016135041A1 (en) * 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
CA2994413A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma, Inc. Methods for treating myeloproliferative disorders
US20200231652A1 (en) * 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
SG10201913576RA (en) 2015-10-01 2020-02-27 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
TWI758267B (zh) 2015-12-14 2022-03-21 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
WO2017134592A1 (en) * 2016-02-03 2017-08-10 Biocon Limited Anti-cd20/immunomodulatory fusion proteins and methods for making same
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CA3038526A1 (en) * 2016-09-27 2018-04-05 Epicentrx, Inc. Immunomodulatory fusion proteins
CN109789183A (zh) * 2016-09-29 2019-05-21 Aebi有限公司 治疗性多靶向构建体及其用途
US11267856B2 (en) 2017-02-27 2022-03-08 Shattuck Labs, Inc. CSF1R-CD40L chimeric proteins
BR112019017298A2 (pt) 2017-02-27 2020-04-14 Shattuck Labs Inc proteínas quiméricas à base de tigit e light
WO2018157163A1 (en) 2017-02-27 2018-08-30 Shattuck Labs, Inc. Vsig8-based chimeric proteins
KR20190129896A (ko) 2017-03-02 2019-11-20 내셔날 리서치 카운실 오브 캐나다 Tgf-β-수용체 엑토도메인 융합 분자 및 그의 용도
KR102635723B1 (ko) * 2017-05-04 2024-02-08 악셀레론 파마 인코포레이티드 Tgf-베타 수용체 유형 ii 융합 단백질 및 이의 용도
CA3061791A1 (en) 2017-05-12 2019-10-29 Jiangsu Hengrui Medicine Co., Ltd. Fusion protein containing tgf-.beta. receptor and medicinal uses thereof
JP2020521759A (ja) * 2017-05-26 2020-07-27 ザ・ジョンズ・ホプキンス・ユニバーシティ 免疫トレランスを調節するための多機能性の抗体−リガンド・トラップ
CN111032092A (zh) * 2017-06-30 2020-04-17 韩国科学技术院 Vegf-grab蛋白与药物的缀合物及其用途
AU2018326877A1 (en) * 2017-09-02 2020-03-05 Abbvie Inc. Anti-EGFR antibody drug conjugates (ADC) and uses thereof
SG11202001762RA (en) * 2017-09-02 2020-03-30 Abbvie Inc Anti-egfr antibody drug conjugates (adc) and uses thereof
CN111511769B (zh) 2017-09-27 2024-05-24 埃皮辛特瑞柯斯公司 免疫调节性融合蛋白
MX2020009394A (es) 2018-03-09 2021-01-15 Agenus Inc Anticuerpos anti-cd73 y métodos de uso de los mismos.
JP2021522307A (ja) 2018-05-06 2021-08-30 アマイ プロテインズ リミテッドＡｍａｉ Ｐｒｏｔｅｉｎｓ Ｌｔｄ． 味及び風味調整剤タンパク質
CA3096844A1 (en) * 2018-05-15 2019-11-21 Merck Patent Gmbh Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
US20220017601A1 (en) 2018-11-09 2022-01-20 Jiangsu Hengrui Medicine Co., Ltd. TGF-beta RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF
CN110563851B (zh) * 2019-08-20 2020-06-12 启辰生生物科技(珠海)有限公司 具有免疫调节功能的融合蛋白、药物组合物、细胞及应用
CN110734498A (zh) * 2019-10-15 2020-01-31 上海科棋药业科技有限公司 一种用于解除免疫抑制的融合蛋白及其应用
CN110964118A (zh) * 2019-11-27 2020-04-07 中国药科大学 一种双特异性融合抗体及其在肿瘤免疫治疗中的应用
MX2022013455A (es) * 2020-04-28 2022-11-16 Sinocelltech Ltd Molecula truncada en el dominio extracelular de tgfbr2, proteina de fusion de molecula truncada en el dominio extracelular de tgfbr2 y anticuerpo anti-egfr, y uso antitumoral de la proteina de fusion.
CN111690070A (zh) * 2020-05-13 2020-09-22 深圳市众循精准医学研究院 一种sPD-1-Fc-sTGFβRII融合蛋白及其应用
WO2022057061A1 (en) * 2020-09-16 2022-03-24 Suzhou Neologics Bioscience Co., Ltd. Pd-l1 antibodies, fusion proteins, and uses thereof
CA3202867A1 (en) * 2020-12-15 2022-06-23 Bicara Therapeutics Inc. Pharmaceutical formulations for fusion proteins
AU2021400979A1 (en) * 2020-12-15 2023-06-29 Bicara Therapeutics Inc. Combination therapy for the treatment of cancer
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CA3230742A1 (en) * 2021-09-03 2023-03-09 Novarock Biotherapeutics, Ltd. Bispecific and trispecific binding proteins to pd-l1, cd137, and/or tgf.beta. and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO105652B1 (ro) * 1988-09-28 1992-11-30 Lilly Co Eli Procedeu de reducere a heterogenitatii anticorpilor monoclonali
RU2120475C1 (ru) * 1990-05-17 1998-10-20 Макс-Планк-Гезельшафт Цур Фердерунг дер Виссеншафтен е.ф. Способ получения представляющего интерес полипептида, гибридная днк (варианты), слитый белок (варианты)
EP1012275A1 (en) 1997-01-31 2000-06-28 University Of Rochester Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
UA83791C2 (ru) * 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
EP2037892B1 (en) * 2006-06-19 2015-03-18 Asklepios Biopharmaceutical, Inc. Modified factor viii and factor ix genes and vectors for gene therapy
CA2671875A1 (en) 2006-12-22 2008-06-03 Ares Trading S.A. Analytical method for analyzing c-terminus truncation
EP2031064A1 (de) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
CN108129573B (zh) 2007-09-21 2021-10-08 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
WO2009114110A1 (en) 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
JP5304275B2 (ja) 2009-01-29 2013-10-02 Ｊｎｃ株式会社 アポクライティン−ｉｉをコードするコドン最適化核酸およびその使用方法
WO2011102845A1 (en) * 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
DK2542590T4 (da) 2010-03-05 2020-07-13 Univ Johns Hopkins Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner
RU2580020C2 (ru) 2011-04-29 2016-04-10 Биокон Рисерч Лимитед Способ снижения гетерогенности антител и способ получения соответствующих антител
US10323081B2 (en) * 2011-07-06 2019-06-18 Genmag A/S Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
US8604447B2 (en) 2011-07-27 2013-12-10 Kla-Tencor Corporation Solar metrology methods and apparatus
CN104334573A (zh) * 2012-04-30 2015-02-04 比奥孔有限公司 靶向/免疫调节性融合蛋白及其制造方法
PL2970512T3 (pl) * 2013-03-12 2019-03-29 Biocon Limited Immunomodulujące białka fuzyjne i sposoby ich otrzymywania
JP2018167875A (ja) * 2017-03-30 2018-11-01 株式会社フジシール 容器包装体及び容器包装体の製造方法

Also Published As

Publication number Publication date
AU2018202982B2 (en) 2019-08-22
BR112015022733A2 (pt) 2017-10-31
CA2902830A1 (en) 2014-10-09
PL2970512T3 (pl) 2019-03-29
CN105121474A (zh) 2015-12-02
ES2704411T3 (es) 2019-03-18
HK1217343A1 (zh) 2017-01-06
EP2970512A1 (en) 2016-01-20
RU2698975C2 (ru) 2019-09-02
WO2014164427A1 (en) 2014-10-09
JP2016512508A (ja) 2016-04-28
US9988456B2 (en) 2018-06-05
US20160009807A1 (en) 2016-01-14
AU2018202982A1 (en) 2018-05-17
CA3081073C (en) 2023-09-12
EP2970512A4 (en) 2016-11-09
CN105121474B9 (zh) 2020-06-19
NZ711445A (en) 2018-06-29
CA2902830C (en) 2023-09-19
RU2018117558A (ru) 2018-10-26
AU2014249405A1 (en) 2015-10-29
US10766963B2 (en) 2020-09-08
RU2018117558A3 (pt) 2019-01-30
RU2662991C2 (ru) 2018-07-31
JP6605444B2 (ja) 2019-11-13
CA3081073A1 (en) 2014-10-09
AU2014249405B2 (en) 2018-02-01
US20180251560A1 (en) 2018-09-06
CN105121474B (zh) 2020-03-31
RU2015140608A (ru) 2017-04-18
AU2014249405C1 (en) 2018-08-16
DK2970512T3 (en) 2019-01-14
BR112015022733B1 (pt) 2023-02-14
EP2970512B1 (en) 2018-10-10
US20200399379A1 (en) 2020-12-24
MY186864A (en) 2021-08-26
JP2019010111A (ja) 2019-01-24

Similar Documents

Publication Publication Date Title
HK1217343A1 (zh) 融合免疫調節蛋白及其製備方法
HK1251589A1 (zh) 靶向/免疫調節性融合蛋白及其製造方法
EP2968551A4 (en) FUSION PROTEINS AND METHOD THEREFOR
IL240034A0 (en) Chimeric proteins based on l1–pd and –pd–l2 and their uses
HK1220466A1 (zh) 愛帕琳融合蛋白和其用途
EP2877854A4 (en) FUSION PROTEINS AND METHOD THEREFOR
EP2943512A4 (en) FUSION BOVINE ANTIBODIES
HRP20190434T1 (hr) Fuzijski protein
PL2986633T3 (pl) Sposoby ekspresji peptydów i białek
HK1220903A1 (zh) 軟骨結合型融合蛋白
PL2983704T4 (pl) Polipeptydy i szczepionki fuzyjne
EP2995313A4 (en) PLACENTA EXTRACTS AND PREPARATION METHODS THEREOF
GB201318840D0 (en) Method and device for protein preparation
EP2985347A4 (en) METHOD FOR DETECTING A PROTEIN STABILITY AND USES THEREOF
EP2854356A4 (en) METHOD AND DEVICE FOR MULTILINK FUSION
HK1218422A1 (zh) 用於鑒定布羅莫結構域抑制化合物的融合蛋白和方法
EP2986725A4 (en) METHOD AND MATERIALS FOR THE SECULATION OF PROTEINS
EP3029071A4 (en) Saxatilin-fc fusion protein and use thereof
GB201308120D0 (en) Recombinant protein and method for its production
AU2013901331A0 (en) Fusion Proteins and Use Thereof
GB201301640D0 (en) Methods and peptides